Meet Cardiovascular Diabetology's Associate Editor of the Year - Dr Natalia Eberhardt

Dr Natalia Eberhardt has recently been awarded with Cardiovascular Diabetology’s annual Associate Editor Award. In this Q&A Natalia shares why she is passionate about researching the complex interplay between cardiovascular diseases and diabetes as well as what she has learnt as Associate Editor.
Meet Cardiovascular Diabetology's Associate Editor of the Year - Dr Natalia Eberhardt
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

It’s one thing to understand science in the lab but seeing how it translates into patient care has reinforced my belief that translating basic research into clinical practice is crucial for improving outcomes.

Congratulations on winning the first edition of Cardiovascular Diabetology’s Associate Editor Award! How does it feel to win the first edition?

Thank you so much! I am truly honored to receive the first edition of this award. It’s an incredible recognition, and I feel deeply grateful for the opportunity. Cardiovascular Diabetology is such a respected journal in the field, and this award not only validates the effort I’ve put into my role as Associate Editor, but also highlights the collaborative environment fostered by the editorial team and the brilliant researchers I work with. I want to especially thank Dr. Enrique Fisman, the founding editor and Editor-in-Chief, for providing me with the chance to contribute to this outstanding journal. I look forward to continuing our work together and supporting the journal’s growth.

First, please do introduce yourself!

I’m Natalia Eberhardt, a senior postdoctoral fellow at NYU Langone Health. My research began with infectious cardiovascular diseases during my PhD in Argentina, and now focuses on how conditions like diabetes, infections, and inflammation affect atherosclerosis. I study the role of immune cells in cardiovascular complications, particularly how immune responses to metabolic disorders influence atherosclerosis. I also serve as Associate Editor for Cardiovascular Diabetology, supporting the peer-review process and publishing impactful research in this critical field.

Why did you choose this research area and what would you say to grad students if they ask whether they should consider this field?

I chose to focus my research on the complex interplay between cardiovascular diseases and other diseases such as type 2 diabetes, due to the significant impact these conditions have on each other. Type 2 diabetes is a well-established risk factor for cardiovascular disease, but the underlying mechanisms connecting the two remain poorly understood. Both conditions share common pathways, including chronic inflammation, immune dysregulation, and metabolic disturbances, which exacerbate each other’s progression. I'm particularly interested in exploring the immune changes that occur in both diseases, as these alterations appear to play a crucial role in driving the onset and worsening of cardiovascular issues in diabetic patients.

To graduate students considering this field, I would say that this area of research offers tremendous opportunities to make a real difference. The intersection of cardiovascular disease, diabetes, and immune response is a rapidly growing field with a significant demand for new insights. If you’re passionate about understanding the underlying mechanisms of complex diseases and using models that closely resemble human conditions to explore these mechanisms, this is a highly rewarding and impactful area to pursue. Your work could directly contribute to better patient care and more effective treatments.

What is your vision for what you’d like to achieve with your research and work?

My ultimate vision is to contribute to a deeper understanding of the mechanisms that link diseases like diabetes, infections, and atherosclerotic cardiovascular disease, with the goal of improving clinical outcomes for patients. One of my key objectives is to help develop personalized treatment strategies that account for the unique needs of individuals with both diabetes and cardiovascular disease. By better stratifying treatments, we can offer more targeted, effective care.

How does a typical working day look like for you?

My typical day is busy but fulfilling, blending research, writing, and editorial work. I spend a lot of time analyzing data, drafting papers, and reviewing information. As Associate Editor for Cardiovascular Diabetology, I oversee manuscript submissions, collaborate with reviewers, and manage the peer-review process. I also stay engaged with the scientific community through peer reviews, meetings with collaborators, and attending conferences. It’s a lot to juggle, but I wouldn’t have it any other way!

You have been working as Associate Editor for Cardiovascular Diabetology since August 2023, what do you like about your work as Associate Editor for the journal?

What I enjoy most as Associate Editor is engaging with groundbreaking research and helping authors refine and improve their work to reach their full potential. I appreciate the diversity of topics in cardiovascular diabetology, from novel therapies to disease mechanisms. It’s rewarding to ensure important findings get the attention they deserve. What makes this experience even more enjoyable is the amazing, supportive team I work with. The collaboration has been excellent, and I’m truly grateful for the strong teamwork and the opportunity to contribute to such a dynamic, cooperative effort.

Now that you’ve worked for over a year on the journal, is the work how you expected it before, or did you have any surprises or challenges?

Overall, the work has been very much in line with my expectations, though there have been some surprises and challenges along the way. One of the most unexpected aspects has been how fast-paced the peer-review process is. The speed with which decisions are made, combined with the passion and dedication of the authors, has been both surprising and exciting. That said, balancing the responsibilities of the journal with my own research can be a bit challenging at times—especially when deadlines overlap. However, despite these challenges, the experience has been incredibly rewarding. It has not only enriched my understanding of the publication process but also helped me grow professionally.

Has the journal work had any impact on your research or views?

Absolutely. Working with the journal has greatly expanded my perspective in many ways. Reviewing a broad range of studies, including topics I hadn’t explored in depth before, has not only deepened my understanding of the field but also inspired new directions for my own research. One of the most valuable aspects has been gaining a deeper clinical insight into how essential basic science is for addressing real-world diseases. It’s one thing to understand science in the lab but seeing how it translates into patient care has reinforced my belief that translating basic research into clinical practice is crucial for improving outcomes. Overall, this experience has been incredibly enriching and has had a lasting impact on both my scientific thinking and clinical perspective.

Is there anything you would like to share with the readers of Cardiovascular Diabetology?

I’d like to take this opportunity to express my sincere gratitude to the entire Cardiovascular Diabetology team, as well as the exceptional administrative staff. It has truly been a pleasure working alongside such a dedicated and supportive group of professionals. To my fellow colleagues and researchers, I encourage you to share the word about Cardiovascular Diabetology—a fantastic platform for high-quality research that continues to make a meaningful impact in our field. I wholeheartedly recommend submitting your work to the journal and contributing to its growing body of knowledge. It’s an honor to be part of this esteemed publication, and I look forward to seeing even more groundbreaking research in the future!

If you are interested in reading more about Cardiovascular Diabetology's Associate Editor Award, visit Cardiovascular Diabetology's homepage,   and if you are interested in becoming Associate Editor, please reach out me as Publisher of Cardiovascular Diabetology

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Type 2 Diabetes
Life Sciences > Health Sciences > Clinical Medicine > Diseases > Diabetes > Type 2 Diabetes
Cardiovascular Diseases
Life Sciences > Health Sciences > Clinical Medicine > Diseases > Cardiovascular Diseases

Related Collections

With collections, you can get published faster and increase your visibility.

Cardiometabolic HFpEF with focus on type 2 diabetes mellitus

This collection aims to highlight the complex interplay between metabolic factors and heart failure with preserved ejection fraction (HFpEF), particularly focusing on type 2 diabetes (T2D). Described as the “single largest unmet need in cardiovascular medicine”, HFpEF has come to represent more than half of all new heart failure diagnoses and associates with a poor 5-year prognosis (40% mortality rate) despite optimal medical treatment. Obesity and diabetes-related HFpEF, also known as cardiometabolic HFpEF (HFpEF), is the most prevalent HFpEF phenotype and its incidence is expected to increase exponentially in decades to come. The presence of T2D contributes to disease development and progression through mechanisms such as insulin resistance, chronic inflammation, endothelial dysfunction, immune dysregulation and myocardial fibrosis. This collection welcomes original articles, meta-analyses and review articles that explore a range of topics from mechanistic studies and therapeutic targets to clinical aspects, pharmacology, epidemiology, and advanced imaging techniques. Our goal is to provide a comprehensive and state-of-the-art overview of this critical area, highlighting the multifaceted nature of HFpEF in cardiometabolic health. This collection aims to bridge the gap between research and clinical application, offering invaluable knowledge for both healthcare professionals and researchers dedicated to improving cardiovascular health. Specifically, the issue will cover the following topics: • Molecular mechanisms of diabetic HFpEF • HFpEF and cardiometabolic disease • Prevalence, risk prediction and prognosis of diabetic HFpEF • Diabetes and hypertension in HFpEF • GLP1-RA and SGLT2i in HFpEF • Artificial intelligence-based approaches in diabetic HFpEF • Sex and gender in diabetic HFpEF • Comorbidities in diabetic HFpEF

Publishing Model: Open Access

Deadline: Ongoing

Perivascular adipose tissue: friend or foe in cardiometabolic disorders

Perivascular adipose tissue (PVAT) has been identified as a key mediator in the maintenance of vascular homeostasis since the groundbreaking work of Soltis and Cassis (1991). PVAT present in the majority of blood vessels throughout the body (with the exception of cerebral and pulmonary arteries), demonstrates regional variations and heterogeneity along the vascular network. Furthermore, PVAT comprises diverse cell types beyond adipocytes. The interconnection between PVAT and blood vessel wall cells is vital for normal vascular function. Recently considered a biomarker and target in pathologic conditions such as atherosclerosis PVAT changes its phenotype under pathologic conditions such as obesity and diabetes. Aging is another factor that modifies this tissue. Hence, the aims of this collection are to highlight: 1) The importance of PVAT in cardiovascular disease, whether in the presence or absence of diabetes. 2) The involvement of PVAT and its heightened impact on arterial stiffness during aging and various diseases. 3) The translational potential of PVAT as an innovative therapeutic target in clinical contexts. For this collection, papers on diabetes, cardiovascular disease, aging, perivascular adipose tissue, obesity, arterial stiffness, gut microbiome, hypercholesterolemia, cholesterol, heart failure, exercise, nutraceuticals, diet, ketogenic diet, oxidative stress, and inflammation are welcome. Along these lines reinforcing the role and mechanisms of PVAT in cardiometabolic diseases is imperative and will help to explain heterogeneity in different vascular beds. Furthermore, exploration into the impact of perivascular adipose tissue (PVAT) on arterial stiffening remains in its early stages, providing limited understanding of this aspect of arterial health. Studies conducted on aging, obesity, and heart failure in preclinical models have directly shown that PVAT promotes or contributes to arterial stiffness. These findings also offer preliminary insights into potential novel targets for intervention. However, there are few interventions that effectively modify the PVAT phenotype to reduce arterial stiffness. A practical approach to bridging preclinical discoveries with clinical applications and establishing PVAT as a therapeutic target for arterial de-stiffening and overall arterial health involves utilizing clinical imaging techniques. For this collection all types of articles are welcome (research articles, commentaries, review articles…).

Publishing Model: Open Access

Deadline: Ongoing